Brand Name
Clofarabine
View Brand InformationFDA approval date: May 10, 2017
Classification: Nucleoside Metabolic Inhibitor
Form: Injection
What is Clofarabine?
Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
Summary: This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Summary: This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as clofarabine, etoposide, cyclophosphamide, vincristine sulfate liposome, dexamethaso...
FLUCLORIC: Randomized Multicentric Phase III Study Comparing the Efficacy of 2 Reduced Intensity Conditioning Regimens (Clofarabine/Busulfan vs Fludarabine/Busulfan) in Adults With AML and Eligible to Allogeneic Stem Cell Transplantation
Summary: Relapse remains the main cause of death in patients with myeloid malignancies, especially after an allotransplant. Using drugs with higher anti-leukemic activity as part of the conditioning regimen is one of the strategies to decrease relapse incidence in this population. Retrospective studies have shown that clofarabine can achieve impressive results compared to the use of fludarabine in acute my...
Related Latest Advances
Brand Information
CLOFARABINE (CLOFARABINE)
1INDICATIONS AND USAGE
Clofarabine Injection
2DOSAGE FORMS AND STRENGTHS
Injection: 20 mg/20 mL (1 mg/mL) clear solution in single-dose vial
3CONTRAINDICATIONS
None.
4ADVERSE REACTIONS
The following clinically significant adverse reactions are discussed in greater detail in other sections of the label:
- Myelosuppression
- Hemorrhage
- Serious Infections
- Hyperuricemia (tumor lysis syndrome)
- Systemic Inflammatory Response Syndrome (SIRS) and Capillary Leak Syndrome
- Venous Occlusive Disease of the Liver
- Hepatotoxicity
- Renal Toxicity
- Enterocolitis
- Skin Reactions
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The following adverse reactions were reported in <5% of the 115 pediatric patients with ALL or AML:
Gastrointestinal Disorders: cecitis, pancreatitis
Hepatobiliary Disorders: hyperbilirubinemia
Immune System Disorders: hypersensitivity
Infections and Infestations: bacterial infection, Enterococcal bacteremia, Escherichia bacteremia, Escherichia sepsis, fungal infection, fungal sepsis, gastroenteritis adenovirus, infection, influenza, parainfluenza virus infection, pneumonia fungal, pneumonia primary atypical, Respiratory syncytial virus infection, sinusitis, staphylococcal infection
Investigations: blood creatinine increased
Psychiatric Disorders: mental status change
Respiratory, Thoracic and Mediastinal Disorder: pulmonary edema
Table 2 lists the incidence of treatment-emergent laboratory abnormalities after clofarabine administration at 52 mg/m
4.2Postmarketing Experience
The following adverse reactions have been identified during post-approval use of clofarabine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Gastrointestinal disorders: gastrointestinal hemorrhage including fatalities.
- Metabolism and nutrition disorders: hyponatremia
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (including fatal cases).
5OVERDOSAGE
There were no known overdoses of clofarabine. The highest daily dose administered to a human to date (on a mg/m
6DESCRIPTION
Clofarabine Injection contains clofarabine, a purine nucleoside metabolic inhibitor. The chemical name of clofarabine is 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine. Its molecular formula is C
7CLINICAL STUDIES
Seventy-eight (78) pediatric patients with ALL were exposed to clofarabine. Seventy (70) of the patients received the recommended pediatric dose of clofarabine 52 mg/m
All patients had disease that had relapsed after and/or was refractory to two or more prior therapies. Most patients, 38/61 (62%), had received >2 prior regimens and 18/61 (30%) of the patients had undergone at least 1 prior transplant. The median age of the treated patients was 12 years, 61% were male, 39% were female, 44% were White, 38% were Hispanic or Latino, 12% were Black or African-American, 2% were Asian and 5% were Other race.
The overall remission (OR) rate (Complete Remission [CR] + CR in the absence of total platelet recovery [CRp]) was evaluated. CR was defined as no evidence of circulating blasts or extramedullary disease, an M1 bone marrow (≤5% blasts), and recovery of peripheral counts [platelets ≥100 × 10
Response rates for these studies were determined by an unblinded Independent Response Review Panel (IRRP).
Table 3 summarizes results for the pediatric ALL study. Responses were seen in both pre-B and T-cell immunophenotypes of ALL. The median cumulative dose was 530 mg (range 29 to 2815 mg) in 1 (41%), 2 (44%) or 3 or more (15%) cycles. The median number of cycles was 2 (range 1 to 12). The median time between cycles was 28 days with a range of 12 to 55 days.
The median duration of CR, including patients who received transplantation, was 47.9 weeks (range 4.3 to 107.7+), where + indicates the patient was still in CR by the study end.
Of 35 patients who were refractory to their immediately preceding induction regimen, 6 (17%) achieved a CR or CRp. Of 18 patients who had at least 1 prior hematopoietic stem cell transplant (HSCT), 5 (28%) achieved a CR or CRp.
Among the 12 patients who achieved at least a CRp, 6 patients achieved the best response after 1 cycle of clofarabine, 5 patients required 2 courses and 1 patient achieved a CR after 3 cycles of therapy.
8REFERENCES
1. OSHA Hazardous Drugs.
9HOW SUPPLIED/STORAGE AND HANDLING
Clofarabine Injection solution is sterile, clear colorless, preservative-free and free from foreign matter. The pH range of the solution is 4.5 to 7.5 and is supplied as follows:
The vial stopper is not made with natural rubber latex.
10PATIENT COUNSELING INFORMATION
Hematologic Toxicity
Advise patients to return for regular blood counts and to report any symptoms associated with hematologic toxicity (such as weakness, fatigue, pallor, shortness of breath, easy bruising, petechiae, purpura, fever) to their physician [see .
Infection
Advise patients of the signs or symptoms of infection (e.g., fever) and report to the physician immediately if any occur [see .
Hepatic and Renal Toxicity
Advise patients to avoid medications including over the counter and herbal medications, which may be hepatotoxic or nephrotoxic, during the 5 days of clofarabine administration. Also, advise patients of the possibility of developing liver function abnormalities and to immediately report signs or symptoms of jaundice. Advise patients of the signs or symptoms of renal failure/acute renal failure [see .
Systemic Inflammatory Response Syndrome (SIRS)/Capillary Leak Syndrome
Advise patients of the signs or symptoms of SIRS, such as fever, tachycardia, tachypnea, dyspnea and symptoms suggestive of hypotension [see .
Pregnancy
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see . Advise female patients of reproductive potential to use effective contraception during treatment with clofarabine and for 6 months after the last dose [see . Advise males with female partners of reproductive potential to use effective contraception during treatment with clofarabine and for 3 months after the last dose [see .
Lactation
Advise females not to breastfeed during treatment with clofarabine and for 2 weeks after the last dose [see .
Gastrointestinal Disorders
Advise patients that they may experience nausea, vomiting, and/or diarrhea with clofarabine. If these symptoms are significant, they should seek medical attention [see .
Rash
Advise patients that they may experience skin rash with clofarabine. If this symptom is significant, they should seek medical attention.
Distributed by:
Eugia US LLC279 Princeton-Hightstown Rd.
E. Windsor, NJ 08520
Manufactured by:
Eugia Pharma Specialities LimitedHyderabad - 500032
India
Advise patients to return for regular blood counts and to report any symptoms associated with hematologic toxicity (such as weakness, fatigue, pallor, shortness of breath, easy bruising, petechiae, purpura, fever) to their physician [see .
Infection
Advise patients of the signs or symptoms of infection (e.g., fever) and report to the physician immediately if any occur [see .
Hepatic and Renal Toxicity
Advise patients to avoid medications including over the counter and herbal medications, which may be hepatotoxic or nephrotoxic, during the 5 days of clofarabine administration. Also, advise patients of the possibility of developing liver function abnormalities and to immediately report signs or symptoms of jaundice. Advise patients of the signs or symptoms of renal failure/acute renal failure [see .
Systemic Inflammatory Response Syndrome (SIRS)/Capillary Leak Syndrome
Advise patients of the signs or symptoms of SIRS, such as fever, tachycardia, tachypnea, dyspnea and symptoms suggestive of hypotension [see .
Pregnancy
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see . Advise female patients of reproductive potential to use effective contraception during treatment with clofarabine and for 6 months after the last dose [see . Advise males with female partners of reproductive potential to use effective contraception during treatment with clofarabine and for 3 months after the last dose [see .
Lactation
Advise females not to breastfeed during treatment with clofarabine and for 2 weeks after the last dose [see .
Gastrointestinal Disorders
Advise patients that they may experience nausea, vomiting, and/or diarrhea with clofarabine. If these symptoms are significant, they should seek medical attention [see .
Rash
Advise patients that they may experience skin rash with clofarabine. If this symptom is significant, they should seek medical attention.
Distributed by:
Eugia US LLC279 Princeton-Hightstown Rd.
E. Windsor, NJ 08520
Manufactured by:
Eugia Pharma Specialities LimitedHyderabad - 500032
India
11PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-20 mg per 20 mL (1 mg / mL) - Container Label
Rx only NDC 55150-326-01
ClofarabineInjection20 mg per 20 mL(1 mg/mL)Must Be Diluted PriorTo Intravenous UseSingle-Dose 20 mL Vial
ClofarabineInjection20 mg per 20 mL(1 mg/mL)Must Be Diluted PriorTo Intravenous UseSingle-Dose 20 mL Vial
12PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-20 mg per 20 mL (1 mg / mL) - Container-Carton (1 Vial)
Rx only NDC 55150-326-01
ClofarabineInjection20 mg per 20 mL(1 mg/mL)Must Be Diluted PriorTo Intravenous UseContains 1 (20 mL)Single-Dose Vialeugia
ClofarabineInjection20 mg per 20 mL(1 mg/mL)Must Be Diluted PriorTo Intravenous UseContains 1 (20 mL)Single-Dose Vialeugia